In older patients with acute myeloid leukemia (AML), the prevention of relapse has remained
one of the major therapeutic challenges, with more than 75% relapses after complete …

This Phase 1/2 study aimed to determine optimal doses of daunorubicin (DNR; mg/m2) and
cytarabine (mg/m2) to be combined with fractionated doses of gemtuzumab ozogamicin …

As the overall prognosis and treatment response rate to standard chemotherapy for acute
myeloid leukemia (AML) remains poor in the older adult population, there is a need for more …

In order to investigate better molecular‐target therapy for acute myeloid leukemia (AML), we
conducted a phase I trial of a combination of gemtuzumab ozogamicin (GO) with …

The therapeutic activity and toxicity profile of gemtuzumab ozogamicin were assessed in 40
patients> 60 years of age with acute myeloid leukemia (AML) who were not considered …

The objective of this work was to determine the safety and efficacy of gemtuzumab
ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the …

Addition of gemtuzumab ozogamicin (GO) to induction chemotherapy improves outcomes in
older patients with acute myeloid leukemia (AML), but it is uncertain whether a fractionated …

Abstract Gemtuzumab ozogamicin (CMA-676, Mylotargâ „¢), a conjugate of a humanized
anti-CD33 monoclonal antibody linked to the cytotoxic antibiotic calicheamicin, has shown …

Abstract Purpose: Gemtuzumab ozogamicin (Mylotarg; Wyeth Laboratories, Philadelphia,
PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a …

This paper discusses background informationand the body of clinical data that has
beenaccumulated to demonstrate the efficacy andsafety of gemtuzumab ozogamicin …